FDA may require additional trial of Portola's AndexXa

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) lost over $700 million in market cap on March 1 after it disclosed late on Feb. 28 that FDA may require an additional randomized study of

Read the full 300 word article

User Sign In